Hims & Hers Health (NYSE:HIMS) Shares Up 11.5% After Analyst Upgrade

Key Points

• Citigroup upgrade lifted HIMS about 11.5% intraday after the bank moved the stock from sell to neutral and raised its price target to $24, with shares trading as high as $25.46 on mid‑day volume of ~19.8M.
• The company’s strategic deal with Novo Nordisk resolves a prior GLP‑1 dispute and gives Hims access to branded Ozempic/Wegovy (injectable and oral), materially reducing litigation risk and creating a clear near‑term revenue opportunity that has spurred bullish analyst moves and heavy call‑option activity.
• Analyst coverage remains mixed (consensus "Hold" with a $30.46 average target); the firm reported a slight EPS beat, approved a $250M share buyback, but faces significant insider selling and an active shareholder investigation, leaving volatility and execution risk intact.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares traded up 11.5% during mid-day trading on Wednesday after Citigroup upgraded the stock from a sell rating to a neutral rating. Citigroup now has a $24.00 price target on the stock, up from their previous price target of $13.25. Hims & Hers Health traded as high as $25.46 and last traded at $26.1660. 19,819,497 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 32,560,256 shares. The stock had previously closed at $23.47.

A number of other equities analysts also recently weighed in on HIMS. Morgan Stanley reduced their price target on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 24th. BTIG Research cut shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a research note on Tuesday. Leerink Partners reduced their price objective on shares of Hims & Hers Health from $20.00 to $17.50 and set a "market perform" rating for the company in a research note on Tuesday, February 24th. Finally, Evercore set a $24.00 target price on Hims & Hers Health in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $30.46.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the firm's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider directly owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares of the company's stock, valued at $226,684.25. The trade was a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 80,463 shares of company stock worth $2,846,696 over the last ninety days. Company insiders own 17.71% of the company's stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Strategic partnership with Novo Nordisk resolves prior GLP‑1 dispute and gives HIMS access to branded Ozempic/Wegovy (injectable and oral formulations) — this materially reduces litigation risk and creates a clear revenue path from GLP‑1 product sales. Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform
• Positive Sentiment: Analyst upgrade: Needham raised HIMS to Buy with a $30 target, citing the Novo Nordisk agreement and reduced legal risk as drivers for materially higher revenue expectations. Upgrades like this can attract fresh institutional flows. Hims & Hers Health NYSE: HIMS Raised to "Buy" at Needham & Company LLC
• Positive Sentiment: Unusually large call‑option activity: investors bought ~322,282 calls (≈128% above normal volume), signalling aggressive bullish positioning that can amplify short squeezes or momentum moves. Watch open interest and expirations. Hims & Hers Health NYSE: HIMS Target of Unusually Large Options Trading NYSE: HIMS
• Positive Sentiment: Management hire: Kathryn Beiser named Chief Communications Officer to lead external/internal comms as HIMS scales — helps with brand management during rapid product and geographic expansion. Hims & Hers Names Kathryn Beiser as Chief Communications Officer
• Neutral Sentiment: Overall analyst coverage remains mixed — the consensus rating is around Hold even as several firms raise price targets; market views vary on sustainability of GLP‑1 revenue and margin contribution. Hims & Hers Health, Inc. NYSE: HIMS Receives Average Rating of "Hold" from Brokerages
• Neutral Sentiment: Analyst price‑target moves are plentiful (Citigroup, Deutsche, BoA coverage mentioned), reflecting re‑rating debates — useful for monitoring potential upside but not unanimous. Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (13 Ratings)
• Negative Sentiment: Legal/investigation overhang: a shareholder/derivative investigation (Kahn Swick & Foti) is active, which could lead to disclosure questions or litigation risk even after the Novo Nordisk settlement. Hims & Hers Health Investigation Initiated
• Negative Sentiment: Volatility/mean‑reversion risk: several pieces warn that the rapid post‑deal rally may be partly driven by short covering and momentum — gains could be volatile and may not reflect sustainable underlying margins until GLP‑1 revenue and unit economics are proven. Hims & Hers stock: why today's gains are unlikely to be sustainable

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock worth $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its stake in Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after buying an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC raised its holdings in Hims & Hers Health by 1.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock valued at $793,000 after acquiring an additional 252 shares during the period. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company's stock valued at $54,000 after acquiring an additional 283 shares during the period. Finally, W.G. Shaheen & Associates DBA Whitney & Co lifted its position in Hims & Hers Health by 4.8% during the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company's stock worth $436,000 after acquiring an additional 350 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Trading Up 14.5%

The business has a fifty day moving average price of $24.31 and a 200-day moving average price of $37.75. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The company has a market cap of $6.12 billion, a P/E ratio of 52.27, a PEG ratio of 4.24 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm's quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.